Effect of smoking on comparative efficacy of antiplatelet agents: Systematic review, meta-analysis, and indirect comparison

BMJ (Online)

Volumn 347, Issue 7927, 2013, Pages

  Gagne, Joshua J ^a   Bykov, Katsiaryana ^a   Choudhry, Niteesh K ^a   Toomey, Timothy J ^a   Connolly, John G ^a   Avorn, Jerry ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PLACEBO; PRASUGREL; TICAGRELOR;

ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; DRUG DOSE COMPARISON; DRUG EFFICACY; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK REDUCTION; SMOKING; SYSTEMATIC REVIEW;

CARDIOVASCULAR DISEASES; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SMOKING;

EID: 84885203222     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f5307     Document Type: Article

References (29)

1. Bowry AD, Brookhart MA, Choudhry NK Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. Am J Cardiol 2008; 101:960-6.
2. Gurbel PA, Nolin TD, Tantry US Clopidogrel efficacy and cigarette smoking status. JAMA 2012; 307:2495-6.
3. Moher D, Liberati A, Tetzlaff J., Altman DG Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339:b2535.
4. Higgins JPT, Altman DG, Sterne JAC. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Collaboration, 2011.
5. Sabatine MS, McCabe CH, Gibson C.M., Cannon CP Design and rationale of clopidogrel as adjunctive reperfusion therapy-thrombolysis in myocardial infarction (CLARITY-TIMI) 28 trial. Am Heart J 2005; 149:227-33.
6. Sabatine MS, Cannon CP, Gibson C.M., Lopez-Sendon JL, Montalescot G, Theroux P., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352:1179-89.
7. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-34.
8. Wells GA, Sultan SA, Chen L, Khan M., Coyle D. Indirect evidence: indirect treatment comparisons in meta-analysis. Canadian Agency for Drugs and Technologies in Health, 2009.
9. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348:1329-39.
10. Berger JS, Bhatt DL, Steinhubl S.R., Shao M., Steg PG, Montalescot G, et al Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation 2009; 120:2337-44.
11. Bhatt DL, Fox KA, Hacke W, Berger P.B., Black HR, Boden WE, et al Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354:1706-17.
12. Cornel JH, Becker RC, Goodman S.G., Husted S., Katus H, Santoso A, et al Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2012; 164:334-42.e1.
13. Desai NR, Mega JL, Jiang S, Cannon C.P., Sabatine MS Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 2009; 53:1273-8.
14. Ferreiro JL, Bhatt D, Ueno M., Bauer D, Angiolillo D. Differential effect of smoking on long-term outcomes in patients with atherosclerotic vascular disease treated with aspirin or clopidogrel: insights from the clopidogrel versus aspirin in patients at risk of ischemic events trial [abstract]. J Am Coll Cardiol 2012; 59:A62.
15. Hochholzer W, Trenk D, Mega J.L., Morath T., Stratz C, Valinia CM, et al Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. Am Heart J 2011; 162:518-26.e5.
16. Mehta SR, Bassand JP, Chrolavicius S, Diaz R., Eikelboom JW, Fox KA, et al Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010; 363:930-42.
17. Roe MT, Armstrong PW, Fox K.A., White HD, Prabhakaren D, Goodman SG, et al Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012; 367:1297-309.
18. Salek FS. Relationship between clopidogrel and cigarette smoking status in patients with acute coronary syndromes without ST-segment elevation myocardial infarction. Pharmacotherapy 2010; 30:154e.
19. Saraff KY, Steinhubl SR, Hsu A.P., Topol EJ Smoking influences the effectiveness of dual antiplatelet therapy on long-term outcomes following PCI. J Am Coll Cardiol 2006; 47:36B.
20. Steinhubl SR, Berger PB, Mann J.T., 3rd, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288:2411-20.
21. Wallentin L, Becker RC, Budaj A, Cannon C.P., Emanuelsson H., Held C, et al Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045-57.
22. Wiviott SD, Braunwald E, McCabe C.H., Montalescot G., Ruzyllo W, Gottlieb S, et al Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001-15.
23. Yusuf S, Zhao F, Mehta S.R., Chrolavicius S., Tognoni G, Fox KK Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502.
24. Aune E, Roislien J, Mathisen M., Thelle DS, Otterstad JE The "smoker's paradox" in patients with acute coronary syndrome: a systematic review. BMC Med 2011; 9:97.
25. Clarke TA, Waskell LA The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003; 31:53-9.
26. Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm 2007; 64:1917-21.
27. Gurbel PA, Bliden KP, Logan D.K., Kereiakes DJ, Lasseter KC, White A, et al The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX Study. J Am Coll Cardiol 2013; 62:505-12.
28. Farid NA, Kurihara A, Wrighton SA Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 2010; 50:126-42.
29. Rahmioglu N, Heaton J, Clement G., Gill R, Surdulescu G, Zlobecka K., et al. Genetic epidemiology of induced CYP3A4 activity. Pharmacogenet Genomics 2011; 21:642-51.